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Tetrahydrobiopterin (BH4) is an essential cofactor for several enzymes, including all three forms of nitric oxide
synthases, the three aromatic hydroxylases, and glyceryl-ether mono-oxygenase. A proper level of BH4 is, therefore,
necessary for the metabolism of phenylalanine and the production of nitric oxide, catecholamines, and serotonin.
BH4 deﬁciency has been shown to be closely associated with diverse neurological psychiatric disorders. Sepiapterin
reductase (SPR) is an enzyme that catalyzes the ﬁnal step of BH4 biosynthesis. Whereas the number of cases of
neuropsychological disorders resulting from deﬁciencies of other catalytic enzymes involved in BH4 biosynthesis
and metabolism has been increasing, only a handful of cases of SPR deﬁciency have been reported, and the role
of SPR in BH4 biosynthesis in vivo has been poorly understood. Here, we report that mice deﬁcient in the Spr gene
(Spr5/5) display disturbed pterin proﬁles and greatly diminished levels of dopamine, norepinephrine, and serotonin,
indicating that SPR is essential for homeostasis of BH4 and for the normal functions of BH4-dependent enzymes.
The Spr5/5 mice exhibit phenylketonuria, dwarﬁsm, and impaired body movement. Oral supplementation of BH4
and neurotransmitter precursors completely rescued dwarﬁsm and phenylalanine metabolism. The biochemical and
behavioral characteristics of Spr5/5 mice share striking similarities with the symptoms observed in SPR-deﬁcient
patients. This Spr mutant strain of mice will be an invaluable resource to elucidate many important issues regarding
SPR and BH4 deﬁciencies.
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Tetrahydrobiopterin (BH4) is an essential cofactor for
multiple enzymes, including phenylalanine-4-hydroxy-
lase (PAH), tyrosine-3-hydroxylase (TH [MIM 191290]),
tryptophan-5-hydroxylase (TPH [MIM 191060]), all
three forms of nitric oxide synthase (NOS1 [MIM
163731], NOS2 [MIM 163730], and NOS3 [MIM
163729]), and glyceryl-ether mono-oxygenase (Tho¨ny et
al. 2000; Blau et al. 2001b). Deﬁciencies in BH4 metab-
olism can affect the function of all these enzymes, leading
to a variety of metabolic syndromes. For example, PAH
converts phenylalanine to tyrosine in the liver, which is
the ﬁrst step in phenylalanine degradation. When PAH
is missing or defective, phenylalanine may reach levels
of 1 mM in the blood, leading to phenylketonuria
(PKU [MIM 261600]) (Scriver and Kaufman 2001).
These levels result in severe damage to early brain de-
velopment unless strict dietary restriction of phenylal-
anine is instituted. Lower levels of phenylalanine (0.12–
0.99 mM; termed “hyperphenylalaninemia”) are usually
considered benign, although dietary modiﬁcation may
be considered at higher levels in this range (Huttenlocher
2000; Scriver and Kaufman 2001). PKU (or “variant
PKU”) can also be caused by defects in BH4 biosynthesis
(Blau et al. 1992; Tho¨ny and Blau 1997; Tho¨ny et al.
1998a, 1998b). Recent studies have shown that PKU-
affected patients with certain BH4 deﬁciencies as well as
PAH mutations beneﬁtted from the supplementation of
BH4 (Spaapen and Rubio-Gozalbo 2003; Fiege et al.
2005). In addition, TH and TPH are rate-limiting en-
zymes for the production of the biogenic amine neuro-
transmitters dopamine, norepinephrine, and seroto-
nin (Fitzpatrick 1999). Deﬁciencies in TH or TPH have
been implicated in recessive Segawa syndrome (MIM
605407), familial infantile parkinsonism (MIM 168600),
and unipolar major depression (MIM 608516) (Ludecke
et al. 1995, 1996; Swaans et al. 2000). BH4 deﬁciency
can present with similar phenotypes (Blau et al. 2001b).
Nitric oxide (NO) is synthesized by the three forms of
NOS (NOS1–NOS3) and has a variety of physiological
roles (Mungrue et al. 2003). Deﬁciencies in NOS func-
tion in human patients because of BH4 biosynthetic de-
fects have not been carefully examined but may well
exist.
BH4 homeostasis is regulated by the de novo biosyn-
thesis pathway, as well as by the salvage pathway and
the de novo regeneration pathway (ﬁg. 1A). BH4 is syn-
thesized from guanosine triphosphate (GTP) through a
cascade of enzymatic modiﬁcations (Tho¨ny et al. 2000;
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Figure 1 Biosynthesis of BH4 and generation of Spr-knockout mice. A, Biosynthesis of BH4, including the possible alternative pathways
(dashed arrows). B, Mouse Spr genomic structure (wild-type), the knockout (KO) construct, and the resulting targeted mutant allele. The Spr
gene consists of three exons. Blackened and unblackened boxes represent exons that encode translated and untranslated regions of SPR,
respectively. Restriction-enzyme sites for EcoRI (E), HindIII (H), NcoI (N), and SacI (S) are indicated. Restriction-enzyme sites in parentheses
indicate the loss of a recognition sequence during construction of the KO vector. The probes (5′ probe and 3′ probe) for Southern-blot analysis
and the expected sizes of fragments from wild-type and mutant Spr loci are shown. To construct the targeting vector, a segment from exon 1
and the entire exon 2 region were replaced with the PGK-neomycin resistance cassette (PGK-Neo). The herpes simplex virus–thymidine kinase
cassette (HSV-TK) was inserted at the 3′ end of the construct, for negative selection with FIAU. C, Southern-blot analysis of embryonic stem
cell clones by use of the 5′ probe. Genomic DNA isolated from embryonic stem cell clones was digested with EcoRI. The 5′ probe detects the
Spr pseudogene (112 kb) as well as the wild-type (9.5 kb) and mutant (4.4 kb) bands in the authentic Spr locus. D, Southern-blot analysis of
pups from Spr/ matings by use of the 3′ probe. Genomic DNA from pups was digested with NcoI. Southern-blot analysis using the authentic
Spr gene-speciﬁc 3′ probe showed 13.3-kb and 9.9-kb bands for the wild-type and mutant alleles, respectively. E, Northern-blot analysis showing
no detectable Spr transcript in the kidney of Spr/ mice.
Blau et al. 2001a, 2001b). The ﬁrst step of de novo
biosynthesis is the conversion of GTP to D-erythro-7,8-
dihydroneopterin triphosphate, which is mediated by
GTP cyclohydrolase I (GTPCH [MIM 600225]). This
reaction is thought to be the rate-limiting step in de novo
biosynthesis. D-erythro-7,8-dihydroneopterin triphos-
phate is then converted to 6-pyruvoyl-tetrahydropterin
(PTP) by 6-pyruvoyl-tetrahydropterin synthase (PTPS
[MIM 261640]) and subsequently to BH4 by sepiapterin
reductase (SPR [MIM 182125]) through reduced nico-
tinamide adenine dinucleotide phosphate (NADPH)–
dependent reduction steps 1–3 (ﬁg. 1A). Although SPR
is known to be the major enzyme in these ﬁnal reduction
steps, aldo-keto reductases (AKR) and carbonyl reduc-
tases (CBR) can also convert PTP to BH4. AKR can
convert PTP to 1′-oxo-2′-hydroxy tetrahydropterin (1′-
oxo-TP) (Milstien and Kaufman 1989; Levine et al.
1990) and can also reduce 1′-hydroxy-2′-oxo-tetrahy-
dropterin (2′-oxo-TP) to BH4 (Park et al. 1991). CBR
can convert PTP to 1′-oxo-TP or to 2′-oxo-TP (Park et
al. 1991). Therefore, in the presence of both AKR and
CBR, BH4 can be synthesized from PTP without SPR.
Bonafe et al. (2001) showed greatly reduced BH4 levels
in the cerebrospinal ﬂuid (CSF) of human patients with
SPR deﬁciency, indicating that such pathways indeed
exist and partially compensate for the lack of SPR in
vivo. However, a detailed assessment of this compen-
satory activity in various organ systems has been lacking.
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In the salvage pathway, sepiapterin is formed non-
enzymatically from 1′-oxo-TP and is converted to 7,8-
dihydrobiopterin (BH2) by SPR (step 4 in ﬁg. 1). BH2 is
then reduced to BH4 by dihydrofolate reductase (DHFR
[MIM 126060]). During the conversion of phenylala-
nine to tyrosine by PAH, BH4 is oxidized to pterin-4a-
carbinolamine (Fitzpatrick 1999). Pterin-4a-carbinol-
amine dehydratase (PCD [MIM 126090]) converts
pterin-4a-carbinolamine to q-dihydrobiopterin, which
is regenerated to BH4 by dihydropteridine reductase
(DHPR [MIM 261630]). The regeneration of BH4 from
pterin-4a-carbinolamine is important because it supplies
BH4 and removes the harmful metabolites produced by
pterin-4a-carbinolamine (Tho¨ny et al. 2000).
Genetic mutations of all the enzymes involved in BH4
homeostasis have been shown to cause BH4 deﬁciencies
(Tho¨ny et al. 2000; Blau et al. 2001a, 2001b). BH4 de-
ﬁciencies manifest very heterogeneous symptoms, de-
pending on individual mutations and other modifying
genes. In general, patients with BH4 deﬁciency exhibit
progressive neuronal deterioration, mental retardation,
convulsions, disturbances of tone and posture, abnormal
movements, hypersalivation, swallowing difﬁculties, and
temperature instability (Blau et al. 1996). BH4 deﬁcien-
cies can be broadly divided into two groups, depending
on the presence of a PKU phenotype. Individuals har-
boring two mutant alleles in GTPCH, PTPS, DHFR,
and PCD display symptoms accompanied by a varying
(mild to severe) degree of PKU (Blau et al. 2001b),
whereas dominantly inherited GTPCH deﬁciency man-
ifests as dopa-responsive dystonia (MIM 128230) with-
out PKU (Blau et al. 2001a).
SPR deﬁciency in a human patient was not reported
until 2001, and thus it had been believed that the absence
of SPR-deﬁcient patients might have been because of the
presence of compensatory pathways via AKR and CBR
(ﬁg. 1A) and because SPR is dispensable for BH4 bio-
synthesis in vivo. Since 2001, when a new diagnostic
method for detecting SPR enzyme activity in cultured
ﬁbroblasts from patients was developed, 15 patients
with SPR deﬁciency have been reported (Bonafe et al.
2001; Elzaouk et al. 2002; Neville et al. 2005; Tetra-
hydrobiopterin Web site). These patients with SPR de-
ﬁciency were initially misdiagnosed as having DHPR
deﬁciency. The pterin metabolic proﬁles of two patients
with SPR mutations described by Bonafe et al. (2001)
showed differences between brain and peripheral tissues.
Bonafe et al. (2001) suggested that these differences
might be the result of different levels of enzymes (i.e.,
AKR, CBR, and DHFR) playing a compensatory role
for the lack of SPR. These results indicate that SPR is
indeed essential for BH4 homeostasis and that a better
understanding of the in vivo role of SPR in the regulation
of BH4 homeostasis would be helpful for the correct
diagnosis of SPR deﬁciency.
To investigate the role of SPR in the regulation of BH4
homeostasis and in BH4 deﬁciency, we generated a
mouse strain deﬁcient in the Spr gene by the gene-
targeting technique. Spr-deﬁcient mice (Spr/) were
born normal, but they developed dwarﬁsm during the
early postnatal period. Spr/ mice appeared to have
greatly reduced levels of BH4 in the brain and liver. Do-
pamine and serotonin levels were also signiﬁcantly re-
duced in the relevant brain areas, and the mice displayed
impaired locomotion activities. Interestingly, unlike re-
sults for human patients, the serum phenylalanine level
in the Spr/ mice was greatly increased. Dwarﬁsm and
high serum phenylalanine levels could be completely re-
versed by oral supplementation of BH4 and neurotrans-
mitter precursors. This Spr mutant strain will be an in-
valuable resource to uncover many important issues
regarding SPR and BH4 deﬁciencies.
Material and Methods
The Spr-knockout mouse strain was generated at theUniversity
of Florida. The mice were maintained under standard speciﬁc-
pathogen–free conditions, and all animal procedures per-
formed were reviewed and approved by the University of Flor-
ida Institutional Animal Care and Use Committee.
Generation of Spr-Knockout Mice
The mouse Spr gene encodes 261 aa and consists of three
exons (ﬁg. 1B) (Ota et al. 1995; Lee et al. 1999). We had
previously isolated a phage clone containing the entire Spr gene
from a 129/SvJ (129) mouse genomic DNA library (Lee et al.
1999). To construct a targeting vector, a 3.3-kb HindIII-SacI
fragment including a part of exon 1 and a 3.8-kb SacI-HindIII
fragment containing the exon 3 region were sequentially in-
serted into the XhoI and XbaI sites, respectively, of the pPNT
vector (Tybulewicz et al. 1991). The phosphoglycerate kinase
(PGK)–neomycin cassette replaced a portion of exon 1, intron
1, and the entire exon 2 encoding the short-chain dehydro-
genase/reductase domain. After electroporation of the linear-
ized construct, G418-resistant and 1-(2-deoxy-2-ﬂuoro-1-b-D-
arabinofuranosyl)-5-iodouracil (FIAU)–resistant colonies were
selected. Approximately 300 double-resistant colonies were
screened by Southern-blot analysis using a 5′ external probe
(5′ probe in ﬁg. 1B). One of the three positive clones was
microinjected into C57BL/6J (B6) blastocysts to generate chi-
meras, which were crossed with B6 mice to establish andmain-
tain the Spr/ mouse line on a mixed 129/B6 hybrid back-
ground. The genotype of offspring from the breeding of het-
erozygous mice was determined with PCR primer sets SprF1
(5′-AAGTGGTGCTGGCAGCCGCCGAT-3′) and NeoP3 (5′-
CGGTGCTGTCCATCTGCACGAGAC-3′), for detection of
the mutant allele, and srex2F (5′-CCTCCATGCTCTGTTTG-
ACT-3′) and srex2R (5′-GTTCCCCTCCTTGCCTAGC-3′), for
detection of the wild-type allele. The genomic region ampliﬁed
by the srex2F and srex2R primer set was deleted in the mutant
allele, and thus no PCR ampliﬁcation occurs for the Spr/
mice.
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Southern-Blot Analysis
DNA extracted from embryonic stem cells and mouse tails
was digested with EcoRI or NcoI, run on a 0.8% agarose gel,
blotted onto Gene Screen plus membrane, and hybridized with
the radiolabeled 5′ probe (for EcoRI-digested DNA) or 3′ probe
(for NcoI-digested DNA) (ﬁg. 1B).
Northern-Blot Analysis
Total RNA was isolated from the kidney and the brain with
a Trizol reagent (Invitrogen). A sample of 7 mg of kidney RNA
or 20 mg of brain RNA was used for Northern-blot analysis
(Pelle and Murphy 1993) with the Spr or Th cDNA probe,
respectively.
Replacement Therapy
Replacement therapy was performed in accord with the
method described by Elzaouk et al. (2003). To prepare the
low-dose solution, 390 mg of BH4-2HCl (Schircks Laborato-
ries), 300 mg of ascorbic acid (Sigma), 44.4 mg of 5-hydroxy-
tryptophan (Sigma), 15 mg of carbidopa (Sigma), and 150 mg
of N-acetyl-L-cysteine (Sigma) were dissolved in 5 ml of H2O.
Dopa solution was prepared by dissolving 63.6 mg of L-dopa
(Sigma) in 1 ml of 0.5 N HCl. The two solutions were mixed
and adjusted to pH 5.0 with sodium citrate. To prepare the
high-dose solution, 780 mg of BH4-2HCl, 600 mg of ascorbic
acid, 57 mg of 5-hydroxytryptophan, 15 mg of carbidopa, and
300 mg of N-acetyl-L-cysteine were dissolved in 5 ml of H2O.
Dopa solution was prepared by dissolving 81 mg of L-dopa
in 1 ml of 0.5 N HCl. The two solutions were mixed and
adjusted to pH 5.0 with sodium citrate and then were frozen
until use. The mixed solution (500 ml per kg body weight) was
administered orally twice a day by use of micropipettes.
Preparation of Mouse Tissues for Pteridine Measurement
The brain and liver were removed immediately after each
mouse was sacriﬁced and were blended in a cold homogenizing
buffer containing 50 mM Tris-HCl (pH 7.5), 0.1 M KCl, 1
mM EDTA, 1 mM dithiothreitol, and proteinase inhibitors
(EDTA-free proteinase inhibitor cocktail [Roche]) by use of an
electric homogenizer (Biospec Products). For the brain tissue,
4 ml/mg of the homogenizing buffer was added, and, for the
liver, 5 ml/mg was added. Homogenates were centrifuged at
15,000 g for 20 min at 4C, and supernatants were kept frozen
at 80C.
Neopterin, Biopterin, and BH4 Measurements
The BH4 level was measured using high-performance liquid
chromatography (HPLC) analysis after iodine oxidation in
acidic or alkaline conditions, as described elsewhere (Fiege et
al. 2004). To measure the amount of neopterin and biopterin,
a volume of either 100 ml of liver or brain homogenates was
used for acidic (or basic) oxidation, followed by the addition
of 100 ml of 0.2 N HCl (or NaOH). The homogenate was then
incubated in the dark for 1 h, after 10 ml of acidic iodine
solution was added (0.9% iodine and 1.8% potassium iodine
in 0.1 N HCl [or NaOH]). The reaction was terminated by
addition of 10 ml of 5% ascorbic acid. Oxidized samples were
ﬁltered using an Ultra-free MC ﬁlter (10,000-MW cutoff [Mil-
lipore]). The ﬁltrates were subjected to HPLC analysis (using
Waters 600E Pump). Concentrations are expressed as pmol
per mg of protein. BH4 levels were derived by subtracting biop-
terin levels under a basic oxidative state (biopterin  BH2)
from the levels under an acidic oxidative state (i.e., total
biopterin p biopterin  BH2  BH4). The separation was
performed on a Spherisorb ODS1 C18 (particle size 5 mm;
length # internal diameter p mm; Waters) by use250# 4.6
of 1 mM potassium phosphate (pH 4.6) with 5% (v/v) meth-
anol at a ﬂow rate of 0.6 ml/min. Pterins were detected by
their native ﬂuorescence (excitation wavelength 350 nm; emis-
sion wavelength 450 nm) by use of a 2475 ﬂuorescence de-
tector (Waters).
Sepiapterin Measurement
Tissue homogenates were ﬁltered with an Ultrafree-MCﬁlter
(10,000-MW cutoff [Millipore]) and were subjected to HPLC.
The separation was performed on a precolumn (Symmetry C8
[5 mm; mm; Waters]) and an analytical column (Sym-20# 3.9
metry C8 [5 mm; mm;Waters]) by use of the method150# 4.6
described by Zorzi et al. (2002), with some modiﬁcations. The
compositions of solvents A and B for gradient elution were
isopropanol:methanol:acetic acid:H2O (0.5:0.5:0.5:98.95
[v/v]) for solvent A and isopropanol:methanol:acetic acid
(49:49:2 [v/v]) for solvent B. The ﬂow rate was maintained
at 0.6 ml/min by use of the following gradient program: solvent
A at 100% for 3.4 min, solvent B at 0%–2% for 8.5 min,
solvent B at 2% for 3.4 min, solvent B at 2%–20% for 17
min, solvent B at 20% for 1.7 min, solvent B at 40% for 8.5
min, and solvent A at 100% for 17 min.
Measurement of Catecholamines, Serotonin, and Other
Related Metabolites
Dopamine, norepinephrine, 3,4-dihydroxyphenylacetic acid
(DOPAC), serotonin, and 5-hydroxyindole acetic acid (HIAA)
levels in several brain regions were measured by HPLC with
electrochemical detection (Blau et al. 1999). The frontal cortex,
caudate putamen, cerebellum, and general area of the cortex
were separated from the brain and were immediately frozen
in liquid N2. Tissue samples were maintained at 80C until
the neurotransmitters and their metabolites were measured.
Tissue was weighed with a minimum of thawing and was then
homogenized in 2 ml of 0.1 N perchloric acid by use of a
Brinkmann Homogenizer. The homogenate was centrifuged at
7,360 g for 20 min. The supernatant was ﬁltered through a
0.22-mm ﬁlter and was injected onto the HPLC column (YMC-
Pac Pro C18 [5 mm; mm; YMC]). The column was250# 4.6
connected to an HP 3390A integrator maintained at 0.5–1.0
mA and to an LDC/Milton Roy Minipump. The mobile phase
consisted of 12.5 mM citric acid, 7.5 mM sodium phosphate
(monobasic), 0.2 mM Na2EDTA, 0.15 mM sodium octyl sul-
fate (35 mg/liter), and 3.5% acetonitrile. The mobile phase
was then passed through a 0.22-mm ﬁlter (Micron Separations)
before being degassed under helium for at least 15 min. All
separations were performed at a ﬂow rate of 2.22 ml/min. The
amounts of neurotransmitters and their metabolites in each
sample were normalized for the weight of the brain tissue from
which they were extracted.
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Microplate Serum Phenylalanine Assay
Serum phenylalanine was measured using a ﬂuorimetric as-
say (McCaman and Robins 1962) modiﬁed for small volumes
and microtiter plate format. In the assay, 7.5 ml of serum was
precipitated with 11.2 ml of 0.3 N trichloroacetic acid and
were chilled on ice for 10 min. Using a 96-well PCR plate, 64
ml of assay cocktail were dispensed into each well. The cocktail
contained 4.40 ml of 0.3 M succinate (pH 5.8), 1.76 ml of 30
mMninhydrin, and 0.880ml of 5 mML-leucyl-L-alanine. Stan-
dards were prepared from 10 mM phenylalanine in 0.3 N
trichloroacetic acid. Each standard and sample was run in
triplicate. Four microliters of each standard was added to three
wells spaced across the microtiter plate. The precipitated serum
samples were centrifuged at 16,000 g for 10 min in a micro-
centrifuge. From each sample, 4 ml of the supernatant was
added to three consecutive wells, and the plate was capped
and incubated in a thermocycler at 60C for 2 h. Copper re-
agent (200 ml; 15 mM Na2CO3, 2.3 mM potassium sodium
tartrate, and 2.4 mM CuSO475H2O) was added to each well
of a 96-well 0.5-ml black ﬂuorimeter plate (Nunc). Additional
copper reagent (100 ml) was added to the incubated samples
in the PCR plate, and then the entire volume was transferred
into the ﬂuorimeter plate. The PCR plate was washed with
another 100 ml of copper reagent, and the wash was added to
the ﬂuorimeter plate. The plate was read twice on an FLx800
Multidetection Microplate Reader (BioTek) with excitation ﬁl-
ter of 380 nm and emission ﬁlter of 508 nm. Both readings
were averaged to calculate the phenylalanine concentration in
each serum sample relative to the standard curve.
Immunohistochemistry
Dopaminergic and noradrenergic neural cell bodies are lo-
cated in the substantia nigra, ventral tegmental area, and locus
ceruleus. The animals were anaesthetized with ketamine, and
perfusion ﬁxation was performed by perfusing transcardially
with ice-cold 10% neutral buffered formalin for 10 min at a
ﬂow rate of 30–40 ml/min. The brains of the animals were
immediately removed and then were ﬁxed in the same solution
overnight. The ﬁxed tissues were embedded in parafﬁn. Co-
ronal sections (3-mm thick) and parasagittal sections (3-mm
thick) were used for the evaluation of immunoreactivities. Im-
munohistochemical staining was performed using EnVision
anti-mouse or anti-rabbit kits (DAKO). Heat-induced antigen
retrieval was required. The sections were placed in a pressure
cooker for 4 min at maximum pressure in 10 mM citrate buffer
(pH 7.0). The sections were pretreated with 0.3% H2O2 in 0.1
M Tris-buffered saline (TBS) (pH 7.4) for 10 min to quench
endogenous peroxidases. Anti-mouse TH (1:50 dilution
[Novocastra]), anti-rabbit TPH (1:50 dilution [Novocastra]),
anti-mouse calbindin (1:40 dilution [Abcam]), and anti-rabbit
AADC (1:50 dilution [BIOMOL]) antibodies were used. The
primary antibodies were applied and incubated for 30 min at
room temperature (TH, TPH, and calbindin) or overnight at
4C (AADC) in a humid chamber. After being washed with
0.1 M TBST (0.1 M TBS and 0.01% Tween 20), sections were
incubated with EnVision anti-mouse or anti-rabbit (DAKO)
polymer for 30 min. Visualization of the antibody complex
was achieved by treatment with 3,3′-diaminobenzidine chro-
mogen substrate solution (DAKO) and counterstaining with
Meyer’s hematoxylin.
Measurement of Insulin-Like Growth Factor 1 (IGF1)
Total IGF1 (MIM 147440) levels in the serum were mea-
sured by radioimmunoassay in accord with the method de-
scribed by Breier et al. (1991). Serum samples were extracted
with acid-ethanol. Then, 25 ml of serum was treated brieﬂy
with 100 ml of acid-ethanol (12.5% 2 N HCl and 87.5%
ethanol) and was incubated for 30 min at room temperature.
After centrifugation at ∼6,000 g for 3 min at room tempera-
ture, 50 ml of the clear supernatant was transferred to a new
tube. The sample was then neutralized with 250 ml of 0.855
M Tris-base and was centrifuged at 10,000 g for 10 min at
4C. The supernatant was then assayed for the IGF1 level. To
determine the recovery of IGF1 from acid-ethanol extraction,
recombinant IGF1 was spiked into the mouse serum at 10, 5,
and 2 ng/ml. Finally, the IGF1 concentration was calculated
by radioimmunoassay. Two sets of standards were routinely
included in each assay to determine IGF1 concentration cal-
culated by a Riasmart program (Packard). The lower limit of
detection for this assay was 1 ng/ml. The intra-assay and in-
terassay coefﬁcients of validation were 6.7% and 10.2%,
respectively.
Behavioral Test
To analyze locomotor activity, we performed two tests for
voluntary movement: four-limb akinesia and turning on a
screen (Szczypka et al. 2001). In the four-limb akinesia test,
the mice were picked up by the tail and were slowly placed
on a surface. The amount of time required for the mice to
move all four limbs was measured. In the turning test, the mice
were placed head-down on a screen positioned at the edge of
a countertop and tilted 60 from the surface. The amount of
time required for the mice to reorient themselves in the op-
posite direction was measured.
Results
Generation of Spr-Knockout Mouse Line
To investigate the role of SPR in mouse development
and in the biosynthesis of BH4, we generated a strain of
mice deﬁcient in the Spr gene, using conventional knock-
out technology. The mouse Spr gene encodes 261 aa and
consists of three exons (Ota et al. 1995; Lee et al. 1999).
As shown in ﬁgure 1B, a knockout construct was gen-
erated by replacing a Spr genomic region, including a
portion of exon 1 and the entire exon 2, with the PGK-
neomycin cassette. Since exon 2 encodes the short-chain
dehydrogenase/reductase domain essential for SPR func-
tion and because the designed deletion leads to a frame-
shift in the subsequent exon 3, the Spr-knockout allele
was expected to be null. Homologous recombination in
embryonic stem cells was conﬁrmed by genomic South-
ern-blot analysis. Using the 5′ probe, we identiﬁed three
positive embryonic stem cell clones from 300 G418- and
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Figure 2 Growth of Spr/ mice and serum IGF1 levels. A, A
45-d-old Spr/ mouse with dwarﬁsh compared with an Spr/ litter-
mate. B,Growth curves of Spr/ (red), Spr/ (blue), and Spr/ (green)
mice. Each line represents an individual mouse. C, Serum IGF1 levels.
Three 4-wk-old mice of each genotype were tested. Values are means
(and SE is indicated above each bar). * , compared with Spr/P ! .01
mice, as determined by Student’s t test.
FIAU-resistant clones (ﬁg. 1C). One of three correctly
targeted embryonic stem cell clones was microinjected
into B6 blastocysts to generate chimeras. The chimeras
were crossed with B6 mice to establish and maintain the
Spr heterozygous (Spr/) mouse line on a mixed 129/
B6 hybrid background. Homozygous mice (Spr/) were
obtained from heterozygote breeding. The 5′ probe de-
tects the Spr pseudogene (Spr-ps1), which lacks the pro-
moter region and exon 3 that are present in the authentic
Spr gene (Lee et al. 1999). Using the 3′ probe, which
detects the Spr locus but not Spr-ps1, we conﬁrmed that
the gene targeting was made on the authentic Spr locus
(ﬁg. 1D). We showed the absence of Spr transcripts in
the kidneys of the Spr/ mice by Northern-blot analysis
(ﬁg. 1E).
Growth Retardation and Reduced Serum IGF1 Levels
in Spr/ Mice
Spr/ mice are viable and fertile and do not display
any detectable abnormalities. Spr/ mice were indistin-
guishable from their littermates at birth, but all Spr/
mice ( ) showed discernible growth retardationn 1 60
within a few days after birth, and almost no gain of
body weight was recorded beyond 2 wk after birth (ﬁg.
2A and 2B). Most Spr/ mice died within 1–2 mo,
whereas a few survived for 2–6 mo. To test whether
dwarﬁsm was affected by littermate competition, Spr/
mice were quarantined from their normal siblings. How-
ever, no signiﬁcant weight gain was observed in these
mice, in comparison with those kept together with their
normal siblings. The growth curve of Spr/ mice was
remarkably similar to that of Pts/ mice that were res-
cued by replacement therapy with high doses of BH4 and
neurotransmitter precursors (Elzaouk et al. 2003). Since
the serum IGF1 levels were signiﬁcantly reduced in the
rescued Pts/ mice with dwarﬁsm, we examined the
serum IGF1 levels in Spr/ mice, using a radioimmu-
noassay. As shown in ﬁgure 2C, the serum IGF1 levels
were severely reduced in Spr/mice, compared with the
levels in the wild-type and Spr/ littermates. This ﬁnding
suggests that reduced IGF1 is a probable cause of the
growth retardation in the Spr/ mice.
Severely Impaired BH4 Biosynthesis in Spr
/ Mice
It has been postulated that, unlike GTPCH and PTPS
function, SPR function can be compensated by AKR and
CBR (Milstien and Kaufman 1989; Levine et al. 1990;
Park et al. 1991). However, the extent to which SPR
deﬁciency affects BH4 homeostasis in vivo has been un-
known. To address this issue, we measured the neop-
terin, total biopterin, BH4, and sepiapterin levels in the
liver and brain of 4-wk-old Spr/ (wild-type), Spr/,
and Spr/ mice (ﬁg. 3). Eight brain samples from each
genotype of mice, six liver samples from Spr/ and
Spr/ mice, and eight liver samples from Spr/ mice
were analyzed. We found a signiﬁcant decrease in BH4
levels in both liver and brain, but the magnitude of the
decrease was different in these two organs. In the liver,
the BH4 level was dramatically reduced (to 1.1% of wild
type) in Spr/mice compared with the controls,whereas
a relatively mild decrease (40.5% of wild type) was de-
tected in the brain of Spr/ mice. We also found dra-
matic sepiapterin accumulation in the brain and liver of
Spr/ mice, compared with that found in the brains and
livers of the Spr/ and Spr/mice. The amount of neop-
terin, a 7,8-dihydroneopterin triphosphate metabolite,
increased moderately in the liver (to ∼3 times that found
in Spr/ mice) and in the brain (to 5 times). These data
show that AKR and CBR partially compensate for the
loss of SPR in both the brain and liver and that the brain
has a greater degree of compensation than the liver does.
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Figure 3 Pteridine levels. Neopterin, total biopterin (tbiopterin),
BH4, and sepiapterin levels in the liver (A) and brain (B) are shown.
Six Spr/, six Spr/, and eight Spr/ mice were used for the liver
tests. Eight mice of each genotype were used for the brain tests. Values
are means (and SE is indicated above each bar). * andP ! .001
** , compared with Spr/ mice, as determined by Student’s tP ! .01
test.
Figure 4 Activities of TH, TPH, and PAH. To determine the TH
enzyme activity, dopamine (A), DOPAC (B), and norepinephrine (C)
levels were measured in the caudate putamen (CPu), cortex (CTX),
and cerebellum (CBL). For TPH activity, serotonin (D) and 5-HIAA
(E) levels were measured in the CTX and CBL. Three Spr/, ﬁve
Spr/, and three Spr/ mice were analyzed. Values are means (and
SE is indicated above each bar). * and ** , comparedP ! .01 P ! .05
with Spr/ mice, as determined by Student’s t test. F, Phenylalanine
levels of 28–44-d-old mice were measured to determine the functional
PAH enzyme activity. Pahenu2 mice harbor a mutation in the Pah gene
that is generated by N-ethyl-N-nitrosourea (ENU) mutagenesis. Five
Spr/ or Spr/ mice (controls), 5 Spr/ mice, and 10 Pahenu2 mice
were used. Values are means (and SE is indicated above each bar).
* , compared with Spr/ mice, as determined by Student’s tP ! .001
test.
Severely Impaired Phenylalanine Metabolism and
Biosynthesis of Catecholamines and Serotonin
in Spr/ Mice
Because BH4 is an essential cofactor for PAH, TH,
and TPH, we then investigated the extent to which the
lowered BH4 level impacted the function of these en-
zymes. With regard to TH and TPH enzyme activities,
we measured the levels of dopamine, DOPAC (a metab-
olite of dopamine), and norepinephrine, for TH, and the
levels of serotonin and 5-HIAA (a metabolite of sero-
tonin), for TPH, in the caudate putamen, cortex, and
cerebellum of the wild-type (Spr/), Spr/, and Spr/
mice. We found that the amount of neurotransmitters
(i.e., dopamine, norepinephrine, and serotonin) was
markedly reduced in the relevant areas of the Spr/
brain. The dopamine levels in the caudate putamen and
cortex of Spr/ mice was 10-fold lower than those in
the caudate putamens and cortexes of Spr/ and Spr/
mice (ﬁg. 4A). DOPAC in the caudate putamen and cor-
tex was below the detection limit in Spr/ mice (ﬁg.
4B). Norepinephrine was also dramatically reduced in
the cortex and cerebellum of Spr/ mice (ﬁg. 4C). The
serotonin level was greatly reduced in the cortex of
Spr/ mice, whereas the 5-HIAA level was comparable
to that in Spr/ and Spr/ mice (ﬁg. 4D and 4E).
Spr/ mice showed remarkably higher serum phenyl-
alanine levels (2,732 mM; ) than did the Spr/ andnp 5
Spr/ controls (∼63 mM; ) (ﬁg. 4F), and the phe-np 5
nylalanine levels were even higher than those of the
Pahenu2 mice (1,701 mM; ), a PKU animal modelnp 10
widely used for Pah mutation studies (Shedlovsky et al.
1993). These data clearly demonstrate that BH4 deﬁ-
ciency in Spr-knockout mice is sufﬁcient to cause im-
paired activity of BH4-dependent enzymes, including
TH, TPH, and PAH.
Reduced TH Protein Level in Nerve Terminals
of Spr/ Mice
TH-immunoreactivity in Pts/ mice declined consid-
erably in the nerve terminals but not in the cell bodies
(Sumi-Ichinose et al. 2001). As described above, the BH4
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Figure 5 Expression of TH in the brain. Brain sections from
Spr/ (A, C, E, and G) and Spr/ (B, D, F, and H) mice were im-
munostained with anti-TH antibody (A, B, C, D, E, and F) or anti-
AADC antibody (G and H). A few unusual TH-immunopositive cells
(red arrowheads) and weakly positive ﬁbers (black arrowheads) are
indicated in the caudate putamen (CPu) of the Spr/ brain (F). Images
E and F are magniﬁed (#400) views of the CPu regions in images C
and D (original magniﬁcation #5), respectively. All mice were 4 wk
old. SN p substantia nigra; VTA p ventral tegmental area.
and dopamine levels in Spr/ mice were comparable to
those found in Pts/ mice, and thus we examined the
localization of TH proteins in cell bodies as well as in
the nerve terminals of Spr/ brains. Whereas TH stain-
ing in the dopaminergic cells of wild-type mouse brains
stretches from the substantia nigra into the caudate pu-
tamen along the dopaminergic ﬁbers, TH staining of the
Spr/ brain is strongly detected in the substantia nigra
but gradually becomes faint along the dopaminergic ﬁ-
bers and ﬁnally disappears near the caudate putamen
region (ﬁg. 5A and 5B). The coronal sections of the
brains in the striatum area further demonstrate the strik-
ing difference between the two groups. Whereas the
nerve ﬁbers were heavily stained with the TH antibody
in the striatum of the wild-type brain (ﬁg. 5C), almost
no staining was detected in the corresponding region of
the Spr/ brain (ﬁg. 5D). A few unusual TH-immuno-
positive cells (red arrowheads in ﬁg. 5F) and weakly
positive ﬁbers (black arrowheads in ﬁg. 5F) were found
in the striatum of the Spr/ brain. To test whether this
difference was the result of the degeneration of dopa-
minergic neurons in the striatum of the Spr/ brains,
we stained the brains of both wild-type and Spr/mice,
using aromatic amino acid decarboxylase (AADC [MIM
107930]) antibodies, which detect dopaminergic neu-
rons. The AADC antibody-staining pattern in the stria-
tum areas of the Spr/ brain was comparable to that
of the wild-type brain, indicating normal development
of dopaminergic neurons in Spr/ mice (ﬁg. 5G and
5H). The immunostaining pattern using calbindin an-
tibodies yielded the same result (data not shown).
Northern-blot analysis showed normal expression of the
Th transcript in the Spr/ brain (data not shown). These
data are consistent with the results in studies of Pts/
mice (Sumi-Ichinose et al. 2001) and suggest that a nor-
mal level of BH4 is required for the stability and/or lo-
calization of TH proteins at nerve ﬁbers. We also stained
the Spr/ brain sections with TPH antibodies and found
no differences in staining pattern or intensity between
the mutant brains compared with controls, showing that
(unlike for TPH function), the expression, stability, and
localization of TPH are unaffected by the lower level of
BH4 (data not shown).
Abnormal Locomotion Activities Exhibited
by Spr/ Mice
Dopaminergic neurons are essential for the regulation
of body movement. Dramatically reduced dopamine lev-
els and the abnormal expression of TH in the striatum
predict impairment of locomotive activities in Spr/
mice. To test this, we used four-limb akinesia and turn-
ing tests to monitor voluntary movement (ﬁg. 6). The
Spr/ mice scored signiﬁcantly worse on both tests than
did the wild-type group, a ﬁnding that presents further
evidence of dysfunction in the nigrostrial pathway and
of reduced dopamine and TH levels in the striatum of
Spr/ mice.
Restoration of Spr-Null Phenotypes by Oral
Supplementation of BH4 and Neurotransmitter
Precursors
To investigate whether the supplementation of BH4
and neurotransmitter precursors can rescue the growth
retardation and other related phenotypes of Spr/mice,
we used the same oral treatment methods and doses used
by Elzaouk et al. (2003) to rescue the Pts/ mice. We
used only two dose ranges (designated as “high” and
“low” doses; see the “Material and Methods” section
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Figure 6 Behavioral defects in Spr/mice.A, Four-limb akinesia
test. The mice were picked up by the tail and slowly placed on a surface.
The time that it took for the mice to move all four limbs was recorded.
B, Turning test. The mice were placed head-down on a screen posi-
tioned at the edge of a countertop and tilted 60 from the surface. The
time required for the mice to reorient themselves in the opposite di-
rection was recorded. The maximum time for each set of these tests
was 2 min. Four mice of each genotype were used. Values are means
(and SE is indicated above each bar). * , compared with theP  .001
Spr/ mice, as determined by Student’s t test.
Figure 7 Rescue of Spr/ mice with BH4 and neurotransmitter
precursors. A and B, Body weights of rescued 4-wk-old mice (A) and
75-d-old mice (B). Values are means (and SE is indicated above each
bar). * , as determined by Student’s t test. C and D, Represen-P ! .01
tative 4-wk-old rescued mice with low-dose (C) or high-dose (D) sup-
plementation. E, Serum IGF1 levels in rescued mice. The nontreated
group (Non) comprised three mice of each genotype; the low-dose–
treated group (Low) comprised two Spr/, three Spr/, and three
Spr/ mice; and the high-dose–treated group (High) comprised two
Spr/, two Spr/, and six Spr/ mice. Serum was collected 6–8 h
after the ﬁnal treatment. Values are means (and SE is indicated above
each bar).
for details) instead of three. We administered supple-
ments orally twice a day, beginning at the newborn stage.
Body weights were recorded every day for 75 d, and the
brains, livers, and serum samples were collected to mea-
sure the levels of BH4 and its derivatives, IGF1, and
phenylalanine after 4 wk of treatment. Figure 7 shows
body weights of controls and experimental Spr/ mice
after 4 wk and 75 d of treatment (ﬁg. 7A and 7B, re-
spectively). Although Spr/ mice treated with either
high- or low-dose supplementation gained more body
weight and developed glossier coats than did nontreated
controls, those administered a low dose gained consid-
erably less than did those given a high dose (ﬁg. 7A–
7D). The serum IGF1 level was almost completely re-
stored in the treatedmutant mice (ﬁg. 7E).We also found
that the phenylalanine levels in rescued Spr/mice were
restored to the control level (data not shown).
In contrast to this rescue of body weight and of serum
levels of IGF1 and phenylalanine by oral supplementa-
tion, there was no rescue of BH4 level in the brain and
little increase in BH4 level in the liver, in comparison
with untreated controls (table 1). In addition, we stained
the high-dose–treated Spr/ brain sections with TH an-
tibodies to test whether the treatment recovered TH lo-
calization in the striatum. The brains, isolated 3 h after
the administration of two high doses at once, showed
no changes in the TH-staining patterns in the rescued
Spr/ brain compared with those of untreated controls
(data not shown).
Discussion
Here, we report the generation and characterization of
mice deﬁcient in the Spr gene, which is involved in BH4
biosynthesis and metabolism. We found that homeosta-
sis of BH4, dopamine, norepinephrine, serotonin, and
phenylalanine are greatly disturbed in Spr/mice,which
exhibit dwarﬁsm and impaired body movement. Oral
supplementation of BH4 and neurotransmitter precur-
sors did not restore BH4 levels but did completely rescue
dwarﬁsm and phenylalanine metabolism.
Pterin proﬁle data in the liver and brain of Spr/mice
showed elevated neopterin and sepiapterin as well as
reduced biopterin and BH4, in comparison with the con-
trol littermates (table 1). The implications of these data
are as follows. First, the BH4 level was markedly re-
duced, but not abolished, in Spr/ mice, which dem-
onstrates that SPR is essential for BH4 homeostasis in
mouse tissues. This result is consistent with recent ﬁnd-
ings in SPR-deﬁcient humans (Bonafe et al. 2001; El-
zaouk et al. 2002; Tetrahydrobiopterin Web site). Sec-
ond, the alternative pathway of BH4 biosynthesis from
PTP, most likely mediated by AKR and CBR, can only
partially compensate for the role of SPR. The degree of
584 The American Journal of Human Genetics Volume 78 April 2006 www.ajhg.org
Table 1













Spr/ .17  .06 8.85  .58 5.97  .42 ND .21  .06 43.41  2.49 38.57  1.80 ND
Spr/ .29  .04 15.81  .94 4.67  .60 ND .35  .08 39.28  1.87 32.36  1.92 ND
Spr/ .89  .08 3.42  .40 2.42  .31 4.75  .43 .71  .10 1.94  .44 .42  .32 5.47  1.04
Low dose:
Spr/ .77 8.69 5.76 ND .37  .04 39.44  5.12 34.89  5.74 ND
Spr/ .41 13.44 8.64 ND .5  .07 49.23  1.3 45.65  1.19 ND
Spr/ .91  .16 6.30  2.34 .58  .05 6.22  .88 .5 1.89 .33 9.05
High dose:
Spr/ .2  .03 8.99  .33 7.24  .42 ND .33  .01 41.41  2.71 36.92  4.16 ND
Spr/ .36  .22 8.58  1.01 6.50  2.01 ND .31  .06 48.90  1.62 45.64  1.34 ND
Spr/ .53  .06 4.00  1.17 1.77  .37 5.68  .58 .34  .03 3.82  1.1 1.86  .60 8.72  .46
NOTE.—ND p not detectable.
BH4 reduction in the liver and brain was signiﬁcantly
different—that is, there was more reduction in the liver
than in the brain. This result is consistent with differ-
ences in pterin proﬁling among the brain (CSF), periph-
eral tissues, and ﬁbroblasts of SPR-deﬁcient patients
(Bonafe et al. 2001). Such a variance is likely the result
of different expression and activities of the enzymes in-
volved in the alternative pathway of BH4 biosynthesis
(i.e., AKR and CBR) and the salvage pathway (i.e., CBR
and DHFR) among different organs and tissues. It may
also be the result of greater use of BH4 in the liver for
conversion of phenylalanine to tyrosine from dietary
phenylalanine. Third, the sepiapterin level was signiﬁ-
cantly elevated in the liver and brain of Spr/ mice,
which suggests that SPR is the major reductase from
sepiapterin to BH2 in the salvage pathway (ﬁg. 1A). To
date, eight SPR-deﬁcient patients’ pterin proﬁles are
available (Bonafe et al. 2001; Elzaouk et al. 2002; Te-
trahydrobiopterin Web site). The sepiapterin level was
reported for two of these patients, both of whom showed
a high level. This elevated level of sepiapterin could be
a signature of the pterin proﬁle in SPR deﬁciency.
We found dramatically reduced levels of dopamine,
norepinephrine, and serotonin in the relevant brain areas
of Spr/ mice, suggesting that the enzymatic functions
of TH and TPH were severely compromised in these
mutant mice. We also showed, using anti-TH immu-
nostaining, that TH localization was normal in the cell
body (substantia nigra) but undetectable in the projected
nerve terminals (caudate putamen) of Spr/ mice (ﬁg.
5). Northern-blot analysis showed no differences in the
TH transcript level among different genotypes. This re-
sult is in accordance with that obtained from Pts/mice
(Sumi-Ichinose et al. 2001) and suggests that a normal
BH4 level is required for the subcellular localization and/
or stability of TH proteins in dopaminergic neurons. BH4
was reported to prevent the nitration of tyrosine residues
on TH mediated by reactive oxygen species (ROS) such
as peroxynitrite or nitrogen dioxide (Kuhn and Geddes
2003). Such protein modiﬁcations by ROS are known
to be irreversible (Agar and Durham 2003), and nitrated
TH has reduced function and stability (Kuhn and Ged-
des 2003). It was also reported that low levels of BH4
can produce ROS rather than NO. Altogether, we pos-
tulate that reduced BH4 in the striatum of Spr
/ mice
elevates ROS and reduces the prevention of nitration on
TH, which in turn decreases the stability and function
of TH. In contrast, whereas serotonin levels were se-
verely reduced, TPH enzyme appeared at normal levels
in the Spr/ brain sections. This may suggest that—
although the reduction in amine neurotransmitters such
as serotonin, norepinephrine, and dopamine might be in
part the result of high serum phenylalanine levels inter-
fering with either amino acid transport in the brain or
the activities of the two biosynthetic enzymes—different
modes of regulation may be employed for the enzyme
activities of TH and TPH, as proposed by Sumi-Ichinose
et al. (2001).
Spr/ mice exhibited severe dwarﬁsm from the early
postnatal period. The growth curve of Spr/ mice is
similar, if not identical, to that of Pts/ mice supple-
mented with the “high” dose (Elzaouk et al. 2003). IGF1
has been shown to play a pivotal role in body growth
(Liu et al. 1993, 1998; Powell-Braxton et al. 1993). Res-
cued Pts/ mice as well as Spr/ mice showed signiﬁ-
cantly reduced serum IGF1, which suggests a causative
relationship between IGF1 deﬁciency and growth retar-
dation in these mutant mice. It has been shown, in D2
dopamine receptor–deﬁcient mice, that dopamine is an
essential factor for growth-hormone release (Brambilla
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et al. 1997; Diaz-Torga et al. 2002). In the absence of
the dopamine signal, growth hormone and hypotha-
lamic growth-hormone–releasing hormone (GHRH)–
induced IGF1 production is impaired, resulting in dwarf-
ism. Elzaouk et al. (2003) have shown normal growth
hormone and thyroxine levels in the rescued Pts/mice
and have suggested chronic malnutrition (due to swal-
lowing difﬁculties or reduced appetite) as a potential
cause of the IGF1 deﬁciency and dwarﬁsm. Our Spr/
mice exhibited low dopamine and IGF1 levels that were
comparable to those of the rescued Pts/ mice. Inter-
estingly, oral supplementation completely rescued the
dwarﬁsm phenotype of Spr/ mice and restored the
IGF1 level, without any apparent change in BH4 levels.
At least one SPR-deﬁcient patient displayed growth re-
tardation (Bonafe et al. 2001). Since the fostering en-
vironments for mice and humans are obviously different,
it remains to be investigated whether growth retardation
is a common feature of SPR deﬁciency between these
two species. More detailed studies are also required for
deciphering the signaling pathway from lowered dopa-
mine to lowered IGF1 for the dwarﬁsm phenotype of
the Spr mutants.
The Spr/ serum contained a high level of phenyl-
alanine that exceeded the levels found in Pahenu2 mice,
a PKU mouse model (Shedlovsky et al. 1993). SPR-
deﬁcient patients displayed abnormal responses in the
phenylalanine loading test, indicating that the PAH func-
tion is somewhat impaired, yet the phenylalanine levels
in these patients appeared to be normal (Bonafe et al.
2001). This suggests that the lowered BH4 is sufﬁcient
for PAH function in the liver of SPR-deﬁcient patients
to maintain the normal phenylalanine homeostasis. The
reason for this discrepancy between SPR-deﬁcient pa-
tients and Spr/ mice is unknown. One simple expla-
nation is that mice and humans have different levels of
the alternative enzyme activities that compensate for the
loss of SPR, so a higher level of BH4 (a level sufﬁcient
for the function of PAH) is produced in human livers
than in mouse livers. Alternatively, a higher metabolic
rate in mice than in humans (Terpstra 2001) may lead
to faster exhaustion of BH4 in mouse livers. Nonetheless,
our data raise some caution about classifying SPR de-
ﬁciency as a “BH4-deﬁciency without PKU” until con-
sistent data are established from a larger patient pool.
We have shown, using the four-limb akinesia and
turning tests, that Spr/ mice displayed impaired body
movement. Additionally, the prolonged crouching pos-
ture and the neglect of grooming habits demonstrated
by the mice indicated depression and social detachment.
The Spr/ mice also displayed a tremor phenotype, a
symptom associated with dystonia and Parkinson dis-
ease. Although these symptoms could be the result of
small body mass and muscle weakness, the behavioral
characteristics observed in Spr/ mice share striking
similarities with the symptoms observed in SPR-deﬁcient
patients, who present psychomotor retardation, spastic-
ity, dystonia, tremors, and growth retardation (Bonafe
et al. 2001; Elzaouk et al. 2002; Neville et al. 2005;
Tetrahydrobiopterin Web site). Patients with dystonia
present dopamine deﬁciency and locomotive impairment
while their dopaminergic neurons are intact. The same
phenomenon was observed in Spr/ mice. In a previous
study, movement abnormalities observed in a 15-year-
old SPR-heterozygous patient developed into dystonia
and tremor 8 years later (Steinberger et al. 2004), which
suggests that Spr/ mice may also exhibit dystonic
symptoms in the future; 1-year-old Spr/ mice are nor-
mal, but it is possible that they will develop additional
symptoms. In addition, SPR was recently reported to be
associated with the PARK3 locus, which is associated
with early-onset Parkinson disease (Karamohamed et al.
2003). Consequently, the fact that a 15-year-old SPR-
heterozygous patient developed a tremor and that SPR
is included in the PARK3 locus suggests that SPR may
be involved in modulating the age at onset of Parkinson
disease.
We succeeded in rescuing phenotypes observed in
Spr/ mice with the high dose of BH4 and neurotrans-
mitter precursors. After the treatment, the body weight
and serum IGF1 and phenylalanine levels of the mice
were restored to normal. TH expression in the brain,
however, remained the same after 4 wk of either high-
or low-dose treatment. In addition, both high- and low-
dose treatment resulted in a prolonged average lifespan.
We have observed normal behavior, vitality, and fertility
in 8-mo-old Spr/ mice treated with the high dose. It
would be of great interest to investigate the change in
the biochemical and behavioral characteristics of the res-
cued Spr/ mice after cessation of the supplementation.
It would also be fascinating to examine whether dopa-
mine alone, without BH4 and serotonin, can produce
complete or partial rescue of the Sprmutant phenotypes.
Recently, hph-1 mice, in which the GTPCH activity
is partially impaired, displayed pulmonary arterial hy-
pertension (MIM 178600) with decreasedNOS3 activity
in the lungs (Khoo et al. 2005; Nandi et al. 2005). Be-
cause of technical limitations, we have not studied NO
and NOS activities in the Spr mutant. Our Spr knockout
mice would be an additional animal model for studying
the impact of lowered BH4 biosynthesis on NOS func-
tions and pulmonary hemodynamics.
We believe that the Spr-knockout mice, as well as tis-
sue-speciﬁc conditional Spr-knockout mice and trans-
genic mice expressing Spr in speciﬁc tissues for rescue
experiments, will be an invaluable resource to address
many important questions regarding SPR and BH4 de-
ﬁciencies. Such studies would provide crucial informa-
tion not only for better diagnostic criteria and treatment
options for human SPR deﬁciency but also for a broad
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ﬁeld of neuropathogenesis, including neurotransmitter
disorders, dopamine-responsive dystonia, mental retar-
dation, PKU, and Parkinson disease.
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